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Abstract	455	
High	 blood	 pressure	 is	 a	 highly	 heritable	 and	 modifiable	 risk	 factor	 for	 cardiovascular	456	
disease.	We	 report	 the	 largest	 genetic	 association	 study	of	blood	pressure	 traits	 (systolic,	457	
diastolic,	 pulse	 pressure)	 to	 date	 in	 over	 one	 million	 people	 of	 European	 ancestry.	 We	458	
identify	535	novel	blood	pressure	loci	that	not	only	offer	new	biological	insights	into	blood	459	
pressure	regulation	but	also	reveal	shared	genetic	architecture	between	blood	pressure	and	460	
lifestyle	 exposures.	 Our	 findings	 identify	 new	 biological	 pathways	 for	 blood	 pressure	461	
regulation	with	potential	for	improved	cardiovascular	disease	prevention	in	the	future.		462	463	
11		
High	 blood	 pressure	 (BP)	 is	 a	 leading	 heritable	 risk	 factor	 for	 stroke	 and	 coronary	 artery	464	
disease	and	was	responsible	 for	an	estimated	7.8	million	deaths	and	148	million	disability	465	
life	years	lost	worldwide	in	2015	alone1.	Studies	indicate	that	an	individual’s	blood	pressure	466	
(BP)	 level	 is	 determined	by	 complex	 interactions	between	 life	 course	exposures	and	 their	467	
genetic	 background2-4.	 Previous	 genetic	 association	 studies	 have	 included	 genome-wide	468	
meta-analyses,	customised	cardiovascular	candidate	gene	centric	analyses	and	evaluation	of	469	
exome	 variation.	 These	 have	 identified	 and	 validated	 variants	 at	 274	 loci,	 with	 modest	470	
effects	on	population	BP	that	in	aggregate	explain	only	~3%	of	the	trait	variance5-12.	471	
Here,	we	report	genome-wide	discovery	analyses	of	BP	traits	(systolic	-	SBP,	diastolic	-	DBP	472	
and	pulse	pressure	-PP)	in	people	of	European	ancestry	drawn	from	UK	Biobank	(UKB)13	and	473	
the	 International	 Consortium	 of	 Blood	 Pressure-Genome	 Wide	 Association	 Studies	474	
(ICBP)11,12.	We	adopted	a	combination	of	a	one	and	two-stage	study	design	to	test	common	475	
and	 low-frequency	 single	 nucleotide	 polymorphisms	 (SNPs)	 with	 minor	 allele	 frequency	476	
(MAF)	 ³	 1%	 in	 association	 with	 BP	 traits	 (Fig.	 1).	 We	 studied	 over	 1	 million	 people	 of	477	
European	descent	across	both	discovery	and	replication,	including	replication	data	from	the	478	
US	Million	Veterans	Program	(MVP)14	and	the	Estonian	Genome	Centre,	University	of	Tartu	479	
(EGCUT)	Biobank15.	480	
Briefly,	UKB	 is	 a	prospective	 cohort	 study	of	 ~500,000	 individuals	 recruited	at	 ages	40-69	481	
years	 who	 have	 been	 richly	 phenotyped	 including	 BP	measurements14.	 Participants	 were	482	
genotyped	 using	 a	 customized	 array	 with	 imputation	 from	 the	 Haplotype	 Reference	483	
Consortium	(HRC)	panel,	yielding	~7	million	SNPs	(imputation	quality	score	(INFO)	³	0.1	and	484	
MAF	 ³	 1%)16.	 After	 quality	 control	 (QC)	 and	 exclusions	 (Online	 Methods)	 we	 performed	485	
genome-wide	 association	 studies	 (GWAS)	 of	 BP	 traits	 using	 data	 from	 458,577	 UKB	486	
participants	of	European	descent	under	an	additive	genetic	model17	(Supplementary	Table	487	
1a).	Following	LD-score	regression18,	genomic	control	was	applied	to	the	UKB	data	prior	to	488	
meta-analysis	(Online	methods).	489	
In	addition,	we	performed	GWAS	analyses	for	BP	traits	 in	the	newly	extended	ICBP	GWAS	490	
data	comprising	77	 independent	 studies	 including	up	 to	299,024	participants	of	European	491	
ancestry	 genotyped	 with	 various	 arrays,	 and	 imputed	 to	 either	 the	 1,000	 Genomes	492	
Reference	 Panel	 or	 the	 HRC	 platforms	 (Supplementary	 Table	 1b).	 After	 QC	 we	 applied	493	
genomic	 control	 at	 the	 individual	 study	 level	 and	 obtained	 summary	 effect	 sizes	 for	 ~7	494	
million	SNPs	with	INFO	³	0.3	and	Cochran’s	Q	statistic19	(test	of	heterogeneity)	filtered	at	P	495	
≥	1	×	10-4	(Online	Methods).			496	
We	then	combined	the	UKB	and	 ICBP	GWAS	results	using	 inverse-variance	weighted	 fixed	497	
effects	 meta-analysis	 (Online	 Methods),	 giving	 a	 total	 discovery	 sample	 of	 757,601	498	
individuals20.			499	
In	 our	 two-stage	 design	 we	 attempted	 replication	 of	 1,062	 SNPs	 at	 P	 <	 1	 ×	 10-6	 from	500	
discovery	with	concordant	effect	direction	between	UKB	and	 ICBP,	using	 the	sentinel	SNP	501	
(i.e.	SNP	with	smallest	P-value	at	the	locus)	after	excluding	the	HLA	region	(chr	6:25-34MB)	502	
and	 all	 SNPs	 in	 Linkage	 Disequilibrium	 (LD)	 (r2	 ≥	 0.1)	 or	 ±500	 Kb	 from	 any	 previously	503	
validated	BP-associated	SNPs	at	the	274	published	loci.	We	used	MVP	(up	to	220,520	people	504	
of	 European	 descent)	 and	 EGCUT	 (up	 to	 28,742	 Europeans)	 for	 independent	 external	505	
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replication14,15	(Supplementary	Table	1c).		Our	replication	criteria	for	the	two-stage	design	506	
were	genome-wide	significance	(P	<	5	×	10-8)	in	the	combined	meta-analysis,	with	P	<	0.01	in	507	
the	replication	data	and	concordant	direction	of	effect	between	discovery	and	replication.			508	
Given	 the	 larger	 size	 of	 the	 two	 discovery	 datasets	 (UKB	 and	 ICBP)	 compared	 with	509	
replication	 resources,	 we	 additionally	 undertook	 a	 one-stage	 design	 with	 internal	510	
replication,	 to	minimize	 the	 risk	 of	missing	 true	 positive	 associations	 from	 our	 two-stage	511	
analysis.	To	ensure	the	robustness	of	this	approach,	and	to	avoid	false	positive	findings,	we	512	
used	P	<	5	×	10-9	as	the	P-value	threshold	from	the	discovery	meta-analysis,	i.e.	an	order	of	513	
magnitude	more	 stringent	 than	 genome-wide	 significance21.	We	also	 required	 an	 internal	514	
replication	 P-value	 of	 <	 0.01	 in	 each	 of	 the	 UKB	 and	 ICBP	 GWAS	 analyses	 and	 with	515	
concordant	direction	of	effect,	to	ensure	support	from	both	data	sources.		516	
We	then	explored	the	putative	function	of	the	BP	associated	signals	using	a	range	of	in	silico	517	
resources,	 including	 expression	 quantitative	 trait	 loci	 (eQTLs),	 tissue	 and	 DNase	 I	 site	518	
enrichment,	 long	 range	 chromatin	 interactions	 (Hi-C),	 pathway	analysis	 and	 ‘druggability’.		519	
We	investigated	metabolomic	signatures	associated	with	our	novel	sentinel	SNPs,	evaluated	520	
the	overlap	with	 lifestyle	exposures	that	 influence	BP,	and	examined	the	co-occurrence	of	521	
BP-associated	 loci	with	other	complex	 traits	and	diseases.	We	also	carried	out	conditional	522	
analyses	 using	 genome-wide	 complex	 trait	 analysis	 (GCTA)22.	 	 Finally,	 we	 developed	 a	523	
genetic	 risk	 score	 and	 performed	 analysis	 to	 model	 the	 impact	 that	 all	 BP-associated	524	
variants	have	on	BP	level,	risk	of	hypertension	(HTN),	other	cardiovascular	diseases	and	on	525	
BP	in	non-European	ancestries.	526	
RESULTS	527	
We	present	a	total	of	535	novel	loci	(Fig.2,	Supplementary	Fig.	1):	325	loci	claimed	from	the	528	
two-stage	design	(Supplementary	Tables	2a-c)	and	an	additional	210	claimed	from	our	one-529	
stage	design	with	 internal	 replication	 (Supplementary	 Tables	 3a-c).	Of	 the	325	 two-stage	530	
variants,	204	would	also	have	met	the	one-stage	criteria,	while	121	were	uniquely	identified	531	
from	our	two-stage	design	(Fig.	3a).	Thus	using	this	dual	approach,	we	were	able	to	identify	532	
large	numbers	of	additional	 loci	 that	would	not	have	been	detected	by	either	 the	one-	or	533	
two-stage	 designs	 alone,	 as	 well	 as	 finding	 considerable	 overlap	 (Fig.	 3a).	 For	 SBP,	 the	534	
distributions	of	effect	 sizes	of	 the	one-stage	 loci	 (median	=	0.219	mmHg	per	allele;	 Inter-535	
Quartile	Range	(IQR)	=	0.202-0.278)	and	two-stage	loci	(median	=	0.224;	IQR	=	0.195-0.267)	536	
are	 similar	within	 the	 discovery	 data	 (P	=	 0.447)	 (Supplementary	 Fig.	 2).	 Of	 the	 210	 loci	537	
found	only	in	the	one-stage	analysis	of	UKB	and	ICBP,	186	are	also	genome-wide	significant	538	
(P	<	5	×	10-8)	in	the	combined	meta-analysis	of	all	four	discovery	and	replication	resources,	539	
with	all	variants,	except	one,	having	concordant	direction	of	effect	between	discovery	and	540	
replication	(Supplementary	Tables	3a-c).	Of	the	remaining	24	SNPs	which	are	not	genome-541	
wide	significant	overall	in	the	combined	meta-analysis,	10	still	have	concordant	direction	of	542	
effect.		543	
We	 confirm	 previous	 findings	 with	 support	 in	 our	 data	 for	 all	 274	 published	 BP	 loci	544	
(Supplementary	 Fig.	 1	 &	 2	 and	 Supplementary	 Table	 4)	 and	 >95%	 of	 the	 previously	545	
reported	SNPs	covered	within	our	data	are	genome-wide	significant.	Only	6	available	SNPs	546	
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did	 not	 reach	 Bonferroni-significance,	 likely	 because	 they	 were	 originally	 identified	 from	547	
non-European	 ancestries	 (e.g.	 rs6749447,	 rs10474346,	 rs11564022),	 or	 from	 a	 gene-age	548	
interaction	 analysis	 (rs16833934).	 In	 addition,	 we	 confirmed	 a	 further	 92	 loci	 that	 had	549	
previously	 been	 reported	 but	 not	 replicated	 (Supplementary	 Table	 5)9.	 Overall,	with	 274	550	
previously	reported	 loci	confirmed,	92	 loci	replicated	for	the	first	 time,	and	535	novel	 loci	551	
identified	here,	there	are	901	BP-associated	loci	in	total.	552	
Discovery	of	novel	genetic	loci	for	blood	pressure	553	
Of	the	535	independent	novel	loci,	363	SNPs	were	associated	with	only	one	trait;	160	with	554	
two	traits	and	12	with	all	three	BP	traits	(Fig.	3b),	reflecting	the	inter-correlations	between	555	
BP	traits	despite	their	different	physiology.		556	
From	the	conditional	analyses	using	GCTA	we	additionally	identified	163	independent	557	
secondary	signals	with	MAF	≥	1%,	which	are	associated	with	BP	at	genome-wide	significance	558	
level	(Supplementary	Table	6).	Of	these	163	secondary	signals,	19	SNPs	are	in	LD	(r2	≥	0.1)	559	
with	previously	reported	secondary	signals,	resulting	in	a	total	of	144	new	secondary	signals	560	
identified	here.	Hence	in	total	there	are	now	over	1,000	independent	BP	signals	reported.	561	
The	estimated	SNP-wide	heritability	(h2)	of	BP	traits	in	our	data	was	0.213,	0.212	and	0.194	562	
for	SBP,	DBP	and	PP	respectively,	and	there	is	a	gain	in	the	percentage	of	BP	variance	563	
explained.	For	example,	for	SBP,	the	percentage	variance	explained	increased	from	2.8	%	for	564	
the	274	previously	published	loci	to	5.7%	for	all	sentinel	and	secondary	SNPs	identified	at	all	565	
901	loci	(Supplementary	Table	7).		566	
Functional	analyses		567	
Our	functional	analyses	approach	is	summarised	in	Supplementary	Figure	3.	First,	for	each	568	
of	the	901	loci	we	annotated	all	SNPs	(based	on	LD	r2	≥	0.8)	to	the	nearest	gene	within	5kb	569	
of	a	SNP.	There	were	1644	genes	in	the	novel	loci	and	962	genes	in	the	known	loci.	Then	we	570	
investigated	 these	 loci	 for	 tissue	 enrichment,	 DNase	 hypersensitivity	 site	 enrichment	 and	571	
pathway	 analyses.	 At	 66	 of	 the	 535	 novel	 loci	 we	 identified	 97	 non-synonymous	 SNPs,	572	
including	8	predicted	to	be	damaging	(Supplementary	Table	8).	573	
We	 used	 chromatin	 interaction	 Hi-C	 data	 from	 endothelial	 cells	 (HUVEC)23,	 neural	574	
progenitor	cells	(NPC),	mesenchymal	stem	cells	(HVMSC)	and	tissue	from	the	aorta	(HAEC)	575	
and	 adrenal	 gland24	 to	 identify	 distal	 associated	 genes.	 There	 were	 498	 novel	 loci	 that	576	
contained	 a	 potential	 regulatory	 SNP	 and	 in	 484	 of	 these	 we	 identified	 long-range	577	
interactions	 in	 at	 least	 one	 of	 the	 tissues	 or	 cell	 types.	We	 found	 several	 potential	 long-578	
range	target	genes	that	do	not	overlap	with	the	sentinel	SNPs	in	the	LD	block.	For	example,	579	
the	TGFB2	gene	forms	a	1.2Mb	long	regulatory	 loop	with	the	SNPs	 in	the	SLC30A10	 locus,	580	
and	 the	 TGFBR1	 promoter	 forms	 a	 100kb	 loop	 with	 the	 COL15A1	 locus	 (Supplementary	581	
Table	8).	582	
Our	 eQTL	 analysis	 identified	 60	 novel	 loci	with	 eQTLs	 in	 arterial	 tissue	 and	 20	 in	 adrenal	583	
tissue	 (Supplementary	 Table	 9);	 this	 is	 a	 substantial	 increase	over	 those	 identified	 in	our	584	
previously	 published	 GWAS	 on	 ~140K	 UKB	 individuals10.	 An	 example	 is	 SNP	 rs31120122	585	
which	 defines	 an	 aortic	 eQTL	 that	 affects	 expression	 of	 the	MED8	 gene	 within	 the	 SZT2	586	
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locus.	 In	 combination	 with	 Hi-C	 interaction	 data	 in	 MSC	 this	 finding	 supports	 a	 role	 for	587	
MED8	 in	 BP	 regulation,	 possibly	 mediated	 through	 repression	 of	 smooth	 muscle	 cell	588	
differentiation.	Hi-C	 interactions	provide	supportive	evidence	 for	 involvement	of	a	 further	589	
36	 arterial	 eGenes	 (genes	whose	 expression	 is	 affected	by	 the	 eQTLs)	 that	were	distal	 to	590	
their	eQTLs	(e.g	PPHLN1,	ERAP2,	FLRT2,	ACVR2A,	POU4F1).	591	
We	investigated	which	transcription	factors	and	chromatin	marks	are	involved	in	regulatory	592	
interactions	 using	 the	 functional	 predictions	 from	 DeepSEA.	 We	 found	 198	 SNPs	 in	 121	593	
novel	 loci	with	predicted	effects	on	 transcription	 factor	binding	or	on	chromatin	marks	 in	594	
tissues	 relevant	 for	 BP	 biology,	 such	 as	 vascular	 tissue,	 smooth	 muscle	 and	 the	 kidney	595	
(Supplementary	Table	8).		596	
We	used	our	genome-wide	data	at	a	false	discovery	rate	(FDR)	<	1%	to	robustly	assess	the	597	
tissue	enrichment	of	BP	 loci	using	DEPICT	and	 identified	enrichment	across	50	tissues	and	598	
cells	 (Supplementary	 Fig	 4;	 Supplementary	 Table	 10a).	 Enrichment	 was	 greatest	 for	 the	599	
cardiovascular	system	especially	blood	vessels	(P	=	1.5	×	10-11)	and	the	heart	(P	=	2.7	×	10-5).	600	
Enrichment	was	high	 in	adrenal	tissue	(P	=	3.7	×	10-4)	and,	for	the	first	time,	we	observed	601	
high	 enrichment	 in	 adipose	 tissues	 (P	 =	 9.8	 ×	 10-9)	 corroborated	 by	 eQTL	 enrichment	602	
analysis	(P	<	0.05)	(Supplementary	Fig.	4;	Supplementary	Table	10a).	Evaluation	of	enriched	603	
mouse	knockout	phenotype	terms	also	points	to	the	importance	of	vascular	morphology	(P	604	
=	6	×	10-15)	and	development	(P	=2.1	×	10-18)	in	BP.	Due	to	the	addition	of	our	novel	BP	loci,	605	
we	 identified	 new	 findings	 from	 both	 the	 gene	 ontology	 and	 protein-protein	 interaction	606	
subnetwork	 enrichments,	 which	 highlight	 the	 TGFb	 (P	 =	 2.3	 ×	 10-13)	 and	 related	 SMAD	607	
pathways	(P	=	7	×	10-15)	(Supplementary	Table	10b,	Supplementary	Fig.	5b-d).		608	
We	used	FORGE25	to	investigate	the	regulatory	regions	for	cell	type	specificity	from	DNase	I	609	
hypersensitivity	 sites,	 which	 showed	 strongest	 enrichment	 (P	 <	 0.001)	 in	 the	 vasculature	610	
and	highly	vascularised	tissues,	as	reported	in	previous	BP	genetic	studies10	(Supplementary	611	
Fig.	6).		612	
Potential	therapeutic	targets	613	
Ingenuity	 pathway	 analysis	 and	 upstream	 regulator	 assessment	 showed	 enrichment	 of	614	
canonical	 pathways	 implicated	 in	 cardiovascular	 disease	 including	 pathways	 targeted	 by	615	
antihypertensive	drugs	(e.g.	nitric	oxide	signalling)	and	also	suggested	some	potential	new	616	
targets,	 such	 as	 relaxin	 signalling.	 	Notably,	 upstream	 regulator	 analysis	 identified	 several	617	
known	 mediators	 of	 BP	 including	 therapeutic	 targets	 such	 as	 angiotensinogen,	 calcium	618	
channels,	 progesterone,	 natriuretic	 peptide	 receptor,	 angiotensin	 converting	 enzyme,	619	
angiotensin	receptors	and	endothelin	receptors	(Supplementary	Fig.	7).			620	
We	 developed	 a	 cumulative	 tally	 of	 functional	 evidence	 at	 each	 variant	 to	 assist	 in	621	
variant/gene	prioritisation	at	each	locus.	622	
We	present	a	summary	of	the	vascular	expressed	genes	contained	within	the	535	novel	loci,	623	
including	 a	 review	 of	 their	 potential	 druggability	 (Supplementary	 Fig.	 8).	 The	 overlap	624	
between	genes	associated	with	BP	and	those	associated	with	antihypertensive	drug	targets,	625	
further	demonstrates	new	genetic	 support	 for	 known	drug	mechanisms.	 For	example,	we	626	
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report	 five	 novel	 BP	 associations	 with	 the	 targets	 of	 five	 antihypertensive	 drug	 classes	627	
(Supplementary	Table	11).	These	include	the	PKD2L1,	SLC12A2,	CACNA1C,	CACNB4	and	CA7	628	
loci,	 which	 are	 targeted	 by	 potassium-sparing	 diuretics	 (amiloride),	 loop	 diuretics	629	
(bumetanide	 and	 furosemide),	 dihydropyridine,	 calcium	 channel	 blockers,	 non-630	
dihydropyridines	 and	 thiazide-like	 diuretics	 (chlortalidone)	 respectively.	 Notably	 in	 all	 but	631	
the	last	case,	functional	variants	in	these	genes	are	the	best	candidates	in	each	locus.		632	
Concordance	of	BP	variants	and	lifestyle	exposures	633	
UK	Biobank	has	collected	extensive	lifestyle	related	data,	some	of	which	are	associated	with	634	
BP	 epidemiologically	 and	 in	 trials.	 These	 include	macronutrients,	water,	 tea,	 caffeine	 and	635	
alcohol	intake,	anthropomorphic	traits,	physical	activity	and	inactivity,	smoking	and	urinary	636	
sodium,	potassium	and	creatinine	excretion14.	We	investigated	whether	sentinel	SNPs	at	the	637	
901	BP	loci	were	associated	with	lifestyle	traits	in	UKB	in	either	the	Stanford	Global	Biobank	638	
Engine	(N	=	327,302)	or	Gene	ATLAS	(N	=	408,455),	with	corrected	P	<	1	×	10-6.		For	example,	639	
we	found	that	a	BP	SNP	rs34783010	in	GIPR	is	associated	with	daily	fruit	intake	(P	=	1.03	×	640	
10-7),	 urinary	 sodium	 and	 creatinine	 concentration	 (P	 =	 1.5	 ×	 10-13	 and	 1.2	 ×	 10-9	641	
respectively),	 body	 mass	 index	 (BMI,	 P	 =	 3.3	 ×	 10-41),	 weight	 (P	 =	 7.3	 ×	 10-35)	 and	waist	642	
circumference	(P	=	7.7	×	10-30);	rs6495122,	near	CPLX3	and	ULK3,	and	rs1378942	in	CSK	are	643	
associated	with	water	(P	=	1.3	×	10-22	and	2.6	x	10-20	respectively),	caffeine	(P	=	1.3	×	10-46	644	
and	2.2	×	10-43)	and	tea	intake	(P	=	7.6	×	10-38	and	8.1	×	10-33),	as	well	as	urinary	creatinine	645	
concentrations	 (P=	 5.6	 ×	 10-8	 and	 P=	 3.2	 x	 10-8	 respectively).	 In	 addition,	 the	 BP	 SNP	646	
rs13107325	 in	SLC39A8,	 is	a	novel	 locus	 for	 frequency	of	drinking	alcohol	 (P	=	3.5	×	10-15)	647	
and	time	spent	watching	TV	(P	=	2.3	×	10-11)	as	well	as	being	associated	with	BMI	(P	=	1.6	×	648	
10-33),	 weight	 (P	 =	 8.8	 ×	 10-16)	and	 waist	 circumference	 (P	 =	 4.7	 ×	 10-11)	 (Supplementary	649	
Table	12).	We	used	unsupervised	hierarchical	clustering	for	the	36	BP	 loci	 that	showed	at	650	
least	 one	 association	 with	 the	 lifestyle	 related	 traits	 in	 UKB	 at	 P	 <	 1	 ×	 10-6	 (Fig.	 4).	 The	651	
heatmap	summarises	the	locus	specific	associations	across	the	range	of	traits	and	highlights	652	
heterogeneous	 effects	 with	 anthropometric	 traits	 across	 the	 range	 of	 loci	 examined.	 For	653	
example,	 it	 shows	a	cluster	of	associations	between	BP	 raising	alleles	and	 increased	adult	654	
height	and	weight	and	another	cluster	of	genes	that	show	associations	between	BP	raising	655	
alleles	 and	 decreased	 adult	 height	 and	 weight.	 We	 note	 that	 some	 observed	 cross-trait	656	
associations	are	in	counter-directions	to	what	may	be	expected	epidemiologically.	657	
Association	lookups	with	other	traits	and	diseases	658	
We	 further	 evaluated	 cross-trait	 and	 disease	 associations	 using	 GWAS	 catalog26,	659	
PhenoScanner27	 and	 DIsGeNET,	 which	 integrates	 data	 from	 expert	 curated	 repositories,	660	
GWAS	 catalogues,	 animal	 models	 and	 the	 literature28,29.	 The	 GWAS	 catalog	 and	661	
PhenoScanner	 search	 of	 published	 GWAS	 showed	 that	 77	 of	 our	 535	 novel	 loci	 (using	662	
sentinel	 SNPs	 or	 proxies;	 r2	≥	 0.8)	 are	 also	 significantly	 associated	 with	 other	 traits	 and	663	
diseases	(Fig.	5,	Supplementary	Table	13).	We	identified	APOE	as	a	highly	cross-related	BP	664	
locus	 showing	 associations	 with	 lipid	 levels,	 cardiovascular	 related	 outcomes	 and	665	
Alzheimer’s	disease,	a	finding	that	highlights	a	common	link	between	cardiovascular	risk	and	666	
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cognitive	 decline	 (Fig.	 5).	 Several	 other	 loci	 overlap	with	 anthropometric	 traits,	 including	667	
BMI,	 birth	 weight	 and	 height	 (Fig	 5).	 DisGeNET	 terms	 related	 to	 lipid	 measurements,	668	
cardiovascular	outcomes	and	obesity	overlap	with	BP	loci	(Fig.	6).		669	
We	 used	 1H	 NMR	 lipidomics	 data	 on	 plasma	 (N=2,022)	 and	 data	 from	 the	 Metabolon	670	
platform	(N=1,941)	for	subsets	of	participants	of	the	Airwave	Health	Monitoring	Study30	for	671	
lookups	 of	 our	 sentinel	 SNPs.	 We	 also	 used	 PhenoScanner	 to	 test	 each	 SNP	 against	672	
published	significant	(P	<	5	×	10-8)	genome	vs	metabolome-wide	associations	in	plasma	and	673	
urine	(Online	Methods).	Ten	BP	SNPs	show	association	with	lipid	particle	metabolites	and	a	674	
further	 31	 SNPs	 (8	 also	 on	 PhenoScanner)	 show	 association	 with	 metabolites	 on	 the	675	
Metabolon	 platform,	 highlighting	 lipid	 pathways,	 amino	 acids	 (glycine,	 serine,	 glutamine),	676	
tri-carboxylic	 acid	 cycle	 intermediates	 (succinylcarnitine)	 and	 drug	 metabolites	677	
(Supplementary	Tables	14	and	15).		These	findings	suggest	a	close	metabolic	coupling	of	BP	678	
regulation	with	lipid,	and	for	the	first	time,	with	energy	metabolism.		679	
Genetic	risk	of	increased	blood	pressure,	hypertension	and	cardiovascular	disease	680	
We	 created	 a	 genetic	 risk	 score	 (GRS)	 for	 BP	 levels	 weighted	 according	 to	 the	 effect	681	
estimates	from	ICBP	(for	known	loci)	and	the	MVP+EGCUT	replication	(for	novel	loci)	across	682	
all	901	loci	(Online	Methods).		The	combination	of	these	BP	variants	was	associated	with	a	683	
10.39	mmHg	higher,	sex-adjusted	mean	SBP	in	UK	Biobank	for	the	comparison	between	the	684	
upper	and	lower	quintiles	of	the	GRS	distribution	(95%	CI:	10.19	to	10.58	mm	Hg,	P	<	1	×	10-685	
300)	 and	 with	 12.85	 mmHg	 difference	 in	 SBP	 (95%	 CI:	 12.57	 to	 13.13,	 P	 <	 1	 ×	 10-300)	686	
comparing	the	upper	and	lower	deciles	(Fig.	7a,	Supplementary	Table	16).	 In	addition,	we	687	
observed	over	two-fold	sex-adjusted	higher	risk	of	hypertension	(OR	2.66;	95%	CI:	2.60	to	688	
2.72;	P	<	1	×	10-300)	between	the	upper	and	lower	quintiles	of	the	GRS	in	UK	Biobank	(Fig.	7).	689	
Sensitivity	analyses	in	the	independent	Airwave	cohort	gave	similar	results	(Supplementary	690	
Table	17).		691	
From	record	linkage	to	Hospital	Episode	Statistics	and	mortality	follow-up	in	UKB	we	show	692	
that	 the	GRS	 is	associated	with	 increased,	 sex-adjusted	 risk	of	 incident	 stroke,	myocardial	693	
infarction	and	all	incident	cardiovascular	outcomes,	comparing	the	upper	and	lower	deciles	694	
of	the	GRS	distribution,	with	odds	ratios	of	1.47	(95%	CI:	1.35	to	1.59,	P	=	1.12	×	10-20),	1.50	695	
(95%	 CI:	 1.28	 to	 1.76,	 P	 =	 7.99	 ×	 10-7)	 and	 1.52	 (95%	 CI:	 1.26	 to	 1.82,	 P	 =	 7.4	 ×	 10-6)	696	
respectively	(Fig.	7b,	Supplementary	Table	16).	697	
Extending	analyses	to	other	ancestries	698	
We	examined	associations	with	BP	of	both	 individual	 SNPs	and	 the	GRS	among	unrelated	699	
individuals	of	African	and	of	 South	Asian	ancestries	 in	UKB,	 for	 the	901	known	and	novel	700	
loci.	 In	comparison	with	the	results	for	European	ancestry,	62.4%,	62.5%	and	64.8%	of	the	701	
variants	 among	 people	 of	 African	 (N=7,782),	 and	 74.2%,	 72.3%	 and	 75%	 of	 South	 Asian	702	
(N=10,323)	ancestry	have	concordant	direction	of	effect	 for	SBP,	DBP	and	PP	 respectively	703	
(Supplementary	 Table	 18;	 Supplementary	 Fig.	 9).	 Pearson	 correlation	 coefficients	 with	704	
effect	estimates	in	Europeans	were	r2=	0.37	and	0.78	for	African	and	South	Asian	ancestries	705	
respectively	 (Supplementary	 Fig.	 10).	We	 then	 applied	 the	 GRS	 derived	 from	 European	706	
ancestry	 findings	 to	unrelated	 individuals	 of	African	 (N=6,970)	 and	 South	Asian	 (N=8,827)	707	
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ancestries.	 BP	 variants	 in	 combination	 were	 associated	 with	 6.1	 mmHg	 (95%	 CI:	 4.50	 to	708	
7.65;	 P	 =	 4.9	 ×	 10-14)	 and	 7.4	mmHg	 (95%	 CI:	 6.00	 to	 8.69;	 P	 =	 1.7	 ×	 10-26)	 higher,	 sex-709	
adjusted	mean	 systolic	 pressure	 among	 individuals	 of	African	 and	 South	Asian	 ancestries,	710	
respectively,	 for	 the	 comparison	 between	 the	 upper	 and	 lower	 quintiles	 of	 the	 GRS	711	
distribution	(Supplementary	Tables	19a	and	19b).	712	
DISCUSSION		713	
Our	study	of	over	1	million	people	offers	an	 important	step	 forward	 in	understanding	the	714	
genetic	architecture	of	BP.	We	have	identified	over	1,000	independent	signals	at	901	loci	for	715	
BP	 traits,	 and	with	 535	 novel	 loci	we	 have	more	 than	 tripled	 the	 number	 of	 BP	 loci	 and	716	
doubled	the	percentage	variance	explained	for	BP.	By	now	explaining	27%	of	the	estimated	717	
heritability	for	BP,	we	make	major	inroads	into	the	missing	heritability	influencing	BP	level	718	
in	 the	 population31.	 These	 findings	 illustrate	 the	 power	 of	 a	 large-scale	 standardised	719	
approach	to	data	collection,	biobanking,	genotyping,	quality	control	and	imputation,	such	as	720	
was	 achieved	 in	UKB.	 The	 novel	 loci	 open	 the	 vista	 of	 entirely	 new	biology	 and	 highlight	721	
gene	regions	in	systems	not	previously	implicated	in	BP	regulation.	This	is	particularly	timely	722	
as	 the	 global	 prevalence	 of	 people	 with	 SBP	 over	 110-115	 mm	 Hg,	 above	 which	723	
cardiovascular	 risk	 increases	 in	a	 continuous	graded	manner,	now	exceeds	3.5	billion	and	724	
those	within	the	treatment	range	exceed	1	billion32,33.	725	
Our	functional	analysis	highlights	the	role	of	the	vasculature	and	associated	pathways	in	the	726	
genetics	underpinning	BP	traits.	We	show	a	role	for	several	loci	in	the	transforming	growth	727	
factor	 beta	 (TGFβ)	 pathway	 including	 SMAD	 family	 genes	 and	 the	TGFβ	 gene	 locus	 itself.	728	
This	 pathway	 affects	 sodium	handling	 in	 the	 kidney,	 ventricular	 remodelling	 and	 recently	729	
plasma	 levels	 of	 TGFβ	 have	 been	 correlated	with	 hypertension	 (Fig.	 8)34,35.	 The	 activin	 A	730	
receptor	 type	 1C	 (ACVR1C)	 gene	 mediates	 the	 effects	 of	 the	 TGFβ	 family	 of	 signalling	731	
molecules.	 	Another	BP	 locus	contains	 the	Bone	Morphogenetic	Protein	2	 (BMP2)	gene	 in	732	
the	 TGFβ	 pathway,	 which	 prevents	 growth	 suppression	 in	 pulmonary	 arterial	 smooth	733	
muscle	 cells	 and	 is	 associated	 with	 pulmonary	 hypertension36.	We	 identified	 another	 BP	734	
locus	 including	 the	 Kruppel-like	 family	 14	 (KLF14)	 gene	 of	 transcription	 factors	which	 are	735	
induced	 by	 low	 levels	 of	 TGFβ	 receptor	 II	 gene	 expression.	 This	 gene	 has	 also	 been	736	
associated	with	type	2	diabetes,	hypercholesterolaemia	and	atherosclerosis37.	737	
Our	analysis	shows	enrichment	of	BP	genes	 in	the	adrenal	tissue.	The	adrenal	gland	has	a	738	
key	role	 in	BP	regulation,	with	autonomous	aldosterone	production	by	 the	adrenal	glands	739	
thought	to	be	responsible	for	5-10%	of	all	hypertension,	rising	to	~20%	amongst	people	with	740	
resistant	 hypertension38.	 Some	 of	 our	 novel	 loci	 are	 linked	 functionally	 to	 aldosterone	741	
secretion39,40.	 For	 example,	 the	CTNNB1	 locus	 encodes	 β-catenin,	 the	 central	molecule	 in	742	
the	canonical	Wnt	 signalling	 system,	 required	 for	normal	adrenocortical	development41,42.	743	
Somatic	adrenal	mutations	of	this	gene	that	prevent	serine/threonine	phosphorylation	lead	744	
to	hypertension	through	the	generation	of	aldosterone-producing	adenomas43,44.	745	
Our	 novel	 loci	 also	 include	 genes	 involved	 in	 vascular	 remodelling,	 such	 as	 vascular	746	
endothelial	 growth	 factor	 A	 (VEGFA),	 the	 gene	 product	 of	 which	 induces	 proliferation,	747	
migration	of	vascular	endothelial	cells	and	stimulates	angiogenesis.	Disruption	of	this	gene	748	
in	mice	resulted	in	abnormal	embryonic	blood	vessel	formation,	while	allelic	variants	of	this	749	
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gene	 have	 been	 associated	 with	microvascular	 complications	 of	 diabetes,	 atherosclerosis	750	
and	 the	 antihypertensive	 response	 to	 enalapril45.	 We	 previously	 reported	 a	 fibroblast	751	
growth	factor	(FGF5)	gene	locus	in	association	with	BP.	Here,	we	additionally	identify	a	new	752	
BP	 locus	 encoding	 FGF9,	 which	 has	 been	 linked	 to	 enhanced	 angiogenesis	 and	 vascular	753	
smooth	muscle	cell	differentiation	by	regulating	VEGFA	expression.		754	
Several	 of	 our	 novel	 loci	 contain	 lipid	 related	 genes	which	 supports	 the	 observed	 strong	755	
associations	across	multiple	cardio-metabolic	traits.		For	example,	the	apolipoprotein	E	gene	756	
(APOE)	encodes	the	major	apoprotein	of	the	chylomicron.	Recently,	APOE	serum	levels	have	757	
been	 correlated	 with	 systolic	 BP	 in	 population-based	 studies	 and	 in	 murine	 knockout	758	
models;	disruption	of	this	gene	led	to	atherosclerosis	and	hypertension46,47.	A	second	novel	759	
BP	locus	contains	the	low-density	lipoprotein	receptor-related	protein	4	(LRP4)	gene	which	760	
may	be	 a	 target	 for	APOE	 and	 is	 strongly	 expressed	 in	 the	 heart	 in	mice	 and	humans.	 In	761	
addition,	 we	 identified	 a	 novel	 locus	 including	 the	 apolipoprotein	 L	 domain	 containing	 1	762	
gene	 (APOLD1)	 that	 is	 highly	 expressed	 in	 the	 endothelium	 of	 developing	 tissues	763	
(particularly	heart)	during	angiogenesis.	764	
Many	of	our	novel	BP	loci	encode	proteins	which	may	modulate	vascular	tone	or	signalling.	765	
For	 example,	 the	 locus	 containing	 urotensin-2	 receptor	 (UTS2R)	 gene	 encodes	 a	 class	 A	766	
rhodopsin	 family	 G-protein	 coupled-receptor	 that	 upon	 activation	 by	 the	 neuropeptide	767	
urotensin	II,	produces	profound	vasoconstriction.	One	of	the	novel	loci	for	SBP	contains	the	768	
relaxin	gene	which	encodes	a	G-protein	coupled	receptor	with	roles	 in	vasorelaxation	and	769	
cardiac	 function,	and	which	 signals	by	phosphatidylinositol	3-kinase	 (PI3K)48,49,	 an	enzyme	770	
which	 inhibits	 vascular	 smooth	muscle	 cell	 proliferation	 and	 neo-intimal	 formation50.	We	771	
identify	 the	PI3K	 gene	here	 as	 a	 novel	 BP	 locus.	We	also	 identify	 the	novel	RAMP2	 locus	772	
which	encodes	an	adrenomedullin	receptor51;	we	previously	identified	the	adrenomedullin	773	
(ADM)	gene	as	a	BP	locus12.	Adrenomedullin	is	known	to	exert	differential	effects	on	BP	in	774	
the	brain	(vasopressor)	and	the	vasculature	(vasodilator).	In	addition,	a	locus	containing	Rho	775	
guanine	nucleotide	exchange	factor	25	(ARHGEF25)	gene	generates	a	factor	which	interacts	776	
with	 Rho	 GTPases	 involved	 in	 contraction	 of	 vascular	 smooth	 muscle	 and	 regulation	 of	777	
responses	to	angiotensin	II52.		778	
We	evaluated	the	901	BP	loci	for	extant	or	potentially	druggable	targets.	We	note	that	loci	779	
encoding	MARK3,	PDGFC,	TRHR,	ADORA1,	GABRA2,	VEGFA	 and	PDE3A	 are	within	 systems	780	
that	have	existing	drugs	not	currently	 linked	to	a	known	antihypertensive	mechanism	and	781	
may	offer	repurposing	opportunities	e.g.	detection	of	SLC5A1	as	the	strongest	repurposing	782	
candidate	in	a	new	BP	locus	which	is	targeted	by	the	type	2	diabetes	drug	canagliflozin.	This	783	
is	 important	 as	 between	 8-12%	 of	 patients	 with	 hypertension	 exhibit	 resistance	 or	784	
intolerance	to	current	therapies	and	repositioning	of	a	therapy	with	a	known	safety	profile	785	
may	reduce	development	costs.	786	
Our	findings	with	 larger	sample	size,	strengthen	our	previously	reported	genetic	risk	score	787	
analysis	 indicating	 that	 all	 BP	 elevating	 alleles	 combined	 could	 increase	 systolic	 BP	 by	 10	788	
mm	Hg	or	more	across	quintiles	or	deciles	of	the	population	distribution,	giving	substantially	789	
increased	 risk	 of	 cardiovascular	 events	 (stroke	 and	 coronary	 disease)10.	 We	 previously	790	
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suggested	that	genotyping	BP	elevating	variants	in	the	young	may	lead	to	targeted	lifestyle	791	
intervention	in	early	life	that	might	attenuate	the	BP	rise	at	older	ages10.	792	
We	 identified	 several	 BP-associated	 loci	 which	 are	 also	 associated	 with	 lifestyle	 traits,	793	
suggesting	a	possible	shared	genetic	architecture	between	BP	and	lifestyle	exposures	known	794	
from	 randomised	 clinical	 trials	 and	 observational	 data	 to	 be	 associated	 with	 BP53.	 We	795	
adjusted	our	BP	GWAS	analyses	for	BMI,	which	should	have	reduced	possible	confounding	796	
effects,	though	we	acknowledge	the	potential	for	collider	bias	between	a	lifestyle	factor	and	797	
BP54.	Nonetheless,	our	findings	of	possible	genetic	overlap	between	loci	associated	with	BP	798	
and	lifestyle	exposures	could	support	renewed	focus	on	altering	specific	lifestyle	measures	799	
known	to	affect	BP55.	800	
Despite	 smaller	 sample	 sizes	 in	 the	 single-variant	 analyses	 of	 non-European	 ancestry	801	
samples,	we	observed	high	concordance	of	the	effects	of	BP	variants	in	people	of	African	(>	802	
62%)	and	South	Asian	(>	72%)	ancestry	for	all	BP	traits.	Furthermore,	the	GRS	analyses	show	803	
that,	in	combination,	BP	variants	identified	in	European	analyses	are	also	associated	with	BP	804	
in	non-European	ancestries,	though	size	of	the	effect	was	30-40%	smaller.	Nonetheless,	new	805	
knowledge	on	the	genetic	architecture	of	BP	in	Europeans	also	extends,	at	least	in	part,	to	806	
populations	of	other	ancestries.	807	
Our	discovery	of	535	novel	loci	from	a	combination	of	a	two-stage	GWAS	with	independent	808	
replication	and	one-stage	GWAS	design	with	internal	replication	illustrates	the	value	of	this	809	
approach	to	minimize	the	effects	of	stochastic	variation	and	heterogeneity.	The	one-stage	810	
approach	 was	 included	 in	 order	 to	 report	 signals	 that	 had	 independent	 and	 concordant	811	
support	(P	<	0.01)	from	both	UKB	and	ICBP	(thus	minimizing	the	impact	of	winners’	curse	on	812	
our	 reported	 findings).	 Indeed,	 all	 but	 two	 of	 the	 210	 SNPs	 discovered	 in	 the	 one-stage	813	
analysis	reach	P	<	5	×	10-6	 in	either	UKB	or	 ICBP	(the	two	exceptions	have	P	=7.8	×	10-6	 in	814	
UKB,	 P	 =1.4	 ×	 10-5	 in	 ICBP;	 and	 P	 =1.2	 ×	 10-5	 in	 UKB,	 P	 =	 5.3	 ×	 10-6	 in	 ICBP).	 To	 further	815	
minimize	 the	 risk	 of	 reporting	 false	 positive	 loci	 within	 our	 one-stage	 design,	 we	 set	 a	816	
stringent	 overall	 discovery	 meta-analysis	 P-value	 threshold	 of	 P	 <	 5	 ×	 10-9,	 an	 order	 of	817	
magnitude	 smaller	 than	 a	 genome-wide	 significance	 P-value,	 in	 line	 with	 thresholds	818	
recommended	 for	 whole	 genome	 sequencing22.	 We	 also	 found	 high	 concordance	 in	 the	819	
direction	of	effects	between	discovery	data	 in	the	one-stage	approach	and	the	replication	820	
resources,	with	similar	distributions	of	effect	sizes	for	the	one-stage	vs	two-stage	discovery	821	
data.		We	note	that	24	of	the	one-stage	SNPs	which	reached	P	<	5	×	10-9	in	discovery	failed	822	
to	reach	genome-wide	significance	(P	<	5	×	10-8)	in	the	combined	meta-analysis	of	discovery	823	
and	replication	resources	and	hence	may	still	require	further	validation	in	future	studies	if	824	
larger	replication	resources	became	available.		825	
The	new	discoveries	reported	here	more	than	triple	the	number	of	loci	for	BP	to	a	total	of	826	
901	and	represent	a	substantial	advance	in	understanding	the	genetic	architecture	of	BP.	By	827	
identifying	so	many	novel	genes	across	the	genome,	these	findings	could	partly	support	an	828	
omnigenic	 model	 for	 complex	 traits	 where	 genome-wide	 association	 of	 multiple	829	
interconnected	 pathways	 is	 observed.	 However,	 as	 our	 strong	 tissue	 enrichment	 shows	830	
particular	 relevance	 to	 the	 biology	 of	 BP	 and	 cardiovascular	 disease56,	 the	 genetic	831	
architecture	 of	 BP	 still	 shows	 trait-specificity,	 which	 could	 argue	 against	 an	 omnigenic	832	
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model.	 Our	 confirmation	 of	 the	 impact	 of	 these	 variants	 on	 BP	 level	 and	 cardiovascular	833	
events,	coupled	with	identification	of	shared	risk	variants	for	BP	and	adverse	lifestyle	could	834	
contribute	to	an	early	life	precision	medicine	strategy	for	cardiovascular	disease	prevention.	835	
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Figure	1.	Study	design	schematic	for	discovery	and	validation	of	loci.	ICBP;	International	1125	
Consortium	for	Blood	Pressure;	N,	sample	size;	QC,	quality	control;	PCA,	principal-component	1126	
analysis;	GWAS,	Genome-wide	Association	Study;	1000G	1000	Genomes;	HRC,	Haplotype	Reference	1127	
Panel;	BP:	blood	pressure;	SNPs,	single	nucleotide	polymorphisms;	BMI,	body	mass	index;	LMM;	1128	
linear	mixed	model;	UKB,	UK	Biobank,	MAF,	minor	allele	frequency;	HLA,	Human	Leukocyte	Antigen;	1129	
MVP,	Million	Veterans	Program;	EGCUT;	Estonian	Genome	Center,	University	of	Tartu;	SBP,	systolic	1130	
blood	pressure;	DBP,	diastolic	blood	pressure;	PP,	pulse	pressure.		1131	
	 	1132	
Genetic/phenotypic data QC → N=458,577
Exclude samples with high missingness/heterozygosity, 
sex discordance, QC failures, missing covariates, 
pregnant, retracted informed consent
restrict to Europeans using PCA
Two-stage analysis
Follow-up SNPs with P < 1 × 10-6 for any BP trait
(with concordant direction of effect for UKB vs ICBP)
Independent Replication meta-analysis
→ Lookups of sentinel SNPs 
in MVP (N=220,520) and EGCUT (N=28,742)
→ combined meta-analysis (N=1,006,863)
(i) genome-wide significant (P < 5 × 10-8) in combined meta
(ii) P < 0.01 in replication meta-analysis
(iii) concordant direction of effect
325 novel replicated loci
from two-stage analysis
SBP (130), DBP (91), PP (104)
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(previously published without 
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Genetic/phenotypic data QC → N=299,024
150,134 previously published (54 cohorts), centrally QC-ed
Plus 148,890 samples from 23 newly QC-ed cohorts. 
Including study-level GC-adjustment
European samples only
ICBP data
N=299,024 from 77 different cohorts
UK Biobank data
N=502,620 with genetic & phenotypic data
One-stage analysis
Consider any novel sentinel lookup SNPs which do 
not replicate from 2-stage analysis
→ UKB-ICBP Internal Replication
(i) P < 5 × 10-9 from UKB+ICBP discovery meta
(ii) P < 0.01 in UKB GWAS
(iii) P < 0.01 in ICBP GWAS meta-analysis
(iv) concordant direction of effect UKB vs ICBP
210 novel loci from one-stage analysis
(internally replicated)
SBP (60), DBP (103), PP (47)
Exclude all SNPs in 274 known BP loci, using SNPs previously reported at time of analysis
Locus Definition: (r2 ≥ 0.1; 1Mb region ±500kb from sentinel SNP)
(also fully exclude HLA region: chr6:25-34 Mb)
ICBP-Plus meta-analysis 
ICBP-GWAS of imputed SNPs (1000G or HRC panels)
Fixed effects inverse variance weighted meta-analysis; 
stringent meta-level QC-filtering
UK Biobank GWAS analysis  
UKB GWAS of HRC imputed SNPs
BP ~ SNP + sex + age + age2 + BMI + array
using BOLT-LMM 
→ LD Score Regression → GC-adjustment
UKB+ICBP- GWAS Discovery meta-analysis (N=757,601)
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Figure	2.	Manhattan	plot	showing	the	minimum	P-value	for	the	association	across	all	blood	1133	
pressure	traits	in	the	discovery	stage	excluding	known	and	previously	reported	variants.	1134	
Manhattan	plot	of	the	discovery	genome-wide	association	meta-analysis	in	757,601	individuals	1135	
excluding	variants	in	274	known	loci.	The	minimum	P-value	across	SBP,	DBP	and	PP	is	presented.	The	1136	
y	axis	shows	the	–log10	P	values	and	the	x	axis	shows	their	chromosomal	positions.	Horizontal	red	1137	
and	blue	line	represents	the	thresholds	of	P	=	5	x	10-8	for	genome-wide	significance	and	P	=	1	x	10-6	1138	
for	selecting	SNPs	for	replication,	respectively.	SNPs	in	blue	are	in	LD	(r2	>	0.8)	with	the	325	novel	1139	
variants	independently	replicated	from	the	2-stage	design	whereas	SNPs	in	red	are	in	LD	(r2	>	0.8)	1140	
with	210	SNPs	identified	through	the	1-stage	design	with	internal	replication.	Any	loci	in	black	or	1141	
grey	that	exceed	the	significance	thresholds	were	significant	in	the	discovery	meta-analysis,	but	did	1142	
not	meet	the	criteria	of	replication	in	the	one-	or	two-stage	designs.	1143	 	1144	
	 	1145	
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Figure	3:	Venn	Diagrams	of	Novel	Loci	Results	(a)	“Comparison	of	1-stage	and	2-stage	design	1146	
analysis	criteria”:	For	all	535	novel	loci,	we	compare	the	results	according	to	the	association	criteria	1147	
used	for	the	one-stage	and	the	two-stage	design.	Two-hundred	and	ten	loci	exclusively	met	the	one-1148	
stage	analysis	criteria	(P	<5x10-9	in	the	discovery	meta-analysis,	P	<	0.01	in	UKB,	P	<	0.01	in	ICBP	and	1149	
concordant	direction	of	effect	between	UKB	and	ICBP).	Of	the	325	novel	replicated	loci	from	the	2-1150	
stage	analysis	(genome-wide	significance	in	the	combined	meta-analysis,	P	<	0.01	in	the	replication	1151	
meta-analysis	and	concordant	direction	of	effect),	204	loci	would	also	have	met	the	one-stage	1152	
criteria,	whereas	121	were	only	identified	by	the	two-stage	analysis.			(b)	“Overlap	of	Associations	1153	
across	Blood	Pressure	Traits”.	For	all	535	novel	loci,	we	show	the	blood	pressure	traits	associated	1154	
with	each	locus.	We	present	the	two-stage	loci	first,	followed	by	the	one-stage	loci.	The	locus	names	1155	
provided	in	alphabetical	order	correspond	to	the	nearest	annotated	gene.	SNPs:	Single	nucleotide	1156	
polymorphisms;	SBP:	systolic	blood	pressure;	DBP:	diastolic	blood	pressure;	PP:	pulse	pressure;	UKB:	1157	
UK	Biobank;	ICBP:	International	Consortium	of	Blood	Pressure	1158	
	1159	
	 	1160	
210 204 121
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Figure	4.	Association	of	blood	pressure	loci	with	lifestyle	traits.	Plot	shows	hierarchical	clustering	of	1161	
BP	loci	based	on	associations	with	lifestyle-related	factors.	For	the	sentinel	SNP	at	each	BP	locus	(x	1162	
axis),	we	calculated	the	-log10(P)*sign(β)	(aligned	to	BP-raising	allele)	as	retrieved	from	the	Gene	1163	
Atlas	catalogue	(http://geneatlas.roslin.ed.ac.uk).	BP	loci	and	traits	were	clustered	according	to	the	1164	
Euclidean	distance	amongst	-log10(P)*sign(β).	Red	squares	indicate	direct	associations	with	the	trait	1165	
of	interest	and	blue	squares	inverse	associations.	Only	SNPs	with	at	least	one	association	at	P	<10-6	1166	
with	at	least	one	of	the	traits	examined	are	annotated	in	the	heat-map.	All	901	loci	are	considered,	1167	
both	known	and	novel:	novel	loci	are	printed	in	bold	font.	SNPs:	Single	Nucleotide	Polymorphisms;	1168	
BP:	Blood	Pressure.	1169	
	1170	
	 	1171	
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Figure	5.	Association	of	blood	pressure	loci	with	other	traits.	Plot	shows	results	from	associations	1172	
with	other	traits	which	were	extracted	from	the	GWAS	catalog	and	PhenoScanner	databases	for	the	1173	
535	novel	sentinel	SNPs	including	proxies	in	Linkage	Disequilibrium	(r2	≥	0.8)	with	genome-wide	1174	
significant	associations.	SBP:	Systolic	Blood	Pressure;	DBP:	Diastolic	Blood	Pressure;	PP:	Pulse	1175	
Pressure;	HR:	Heart	Rate;	ECG:	Electrocardiographic	traits;	CAD:	Coronary	Artery	Disease	CHD;	1176	
Coronary	Heart	Disease	MI;	Myocardial	Infraction;	T2D:	Type	II	Diabetes.	1177	
	1178	
	 	1179	
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Figure	6.	Association	of	blood	pressure	loci	with	other	traits.	Plots	(a)	and	(b)	show	overlap	1180	
between	variants	associated	to	(a)	traits	and	(b)	diseases	in	the	manually-curated	version	of	the	1181	
DisGeNET	database,	and	all	variants	in	LD	r2>0.8	with	the	known	(red	bars)	SNPs	from	the	274	1182	
published	loci,	and	all	(green	bars)	BP	variants	from	all	901	loci.	Numbers	on	top	of	the	bars	denote	1183	
the	number	of	SNPs	included	in	DisGeNET	for	the	specific	trait	or	disease.	Traits/diseases	with	an	1184	
overlap	of	at	least	5	variants	in	LD	with	all	markers	are	shown.	The	Y	axis	shows	the	percentage	of	1185	
variants	associated	with	the	diseases	that	is	covered	by	the	overlap.	For	the	sake	of	clarity,	the	1186	
DisGeNET	terms	for	blood	pressure	and	hypertension	are	not	displayed,	whereas	the	following	1187	
diseases	have	been	combined:	coronary	artery	disease	(CAD),	coronary	heart	disease	(CHD)	and	1188	
myocardial	infarction	(MI);	prostate	and	breast	carcinoma;	Crohn's	and	inflammatory	bowel	1189	
diseases.	1190	
	1191	
 1192	1193	
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Figure	7.	Relationship	of	deciles	of	the	genetic	risk	score	(GRS)	based	on	all	901	loci	with	blood	1194	
pressure,	risk	of	hypertension	and	cardiovascular	disease	in	UK	Biobank.	The	plots	show	sex-1195	
adjusted	(a)	mean	systolic	blood	pressure	(SBP)	and	odds	ratios	of	hypertension	(HTN)	and	(b)	odds	1196	
ratios	of	incident	cardiovascular	disease	(CVD),	myocardial	infarction	(MI)	and	stroke,	comparing	1197	
each	of	the	upper	nine	GRS	deciles	with	the	lowest	decile;	dotted	lines	represent	the	upper	95%	1198	
confidence	intervals.		1199	
	 	1200	
a b
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Figure	8:	Known	and	novel	BP	associations	in	the	TGFβ	signalling	pathway.	Genes	with	known	1201	
associations	with	BP	are	indicated	in	cyan.	Genes	with	novel	associations	with	BP	reported	in	this	1202	
study	are	indicated	in	red.	TGFβ	pathway	was	derived	from	an	ingenuity	canonical	pathway.	BP:	1203	
Blood	Pressure.	1204	 	1205	
	1206	
	1207	
ONLINE	METHODS	1208	
UK	Biobank	(UKB)	data	1209	
We	 performed	 a	 Genome	 Wide	 Association	 Study	 (GWAS)	 analysis	 in	 458,577	 UKB	1210	
participants13	 (Supplementary	 Methods).	 These	 consist	 of	 408,951	 individuals	 from	 UKB	1211	
genotyped	at	825,927	variants	with	a	custom	Affymetrix	UK	Biobank	Axiom	Array	chip	and	1212	
49,626	 individuals	 genotyped	 at	 807,411	 variants	 with	 a	 custom	 Affymetrix	 UK	 BiLEVE	1213	
Axiom	Array	chip	from	the	UK	BiLEVE	study57,	which	is	a	subset	of	UKB.	SNPs	were	imputed	1214	
centrally	by	UKB	using	a	reference	panel	that	merged	the	UK10K	and	1000	Genomes	Phase	1215	
3	panel	as	well	as	the	Haplotype	Reference	Consortium	(HRC)	panel58.		For	current	analysis	1216	
only	SNPs	imputed	from	the	HRC	panel	were	considered.	1217	
UKB	phenotypic	data	1218	
Following	 Quality	 Control	 (QC)	 (Supplementary	 Methods),	 we	 restricted	 our	 data	 to	 a	1219	
subset	 of	 post-QC	 individuals	 of	 European	 ancestry	 combining	 information	 from	 self-1220	
reported	and	genetic	data	(Supplementary	Methods)	resulting	in	a	maximum	of	N=458,577	1221	
individuals	(Fig.	1,	Supplementary	Fig.	11).		1222	
Three	 BP	 traits	 were	 analysed:	 systolic	 (SBP),	 diastolic	 (DBP)	 and	 pulse	 pressure	 (PP)	1223	
(difference	between	SBP	and	DBP).	We	calculated	the	mean	SBP	and	DBP	values	from	two	1224	
automated	(N=418,755)	or	two	manual	(N=25,888)	BP	measurements.		For	individuals	with	1225	
35		
one	manual	and	one	automated	BP	measurement	(N=13,521),	we	used	the	mean	of	these	1226	
two	values.	For	individuals	with	only	one	available	BP	measurement	(N=413),	we	used	this	1227	
single	value.	After	calculating	BP	values,	we	adjusted	for	medication	use	by	adding	15	and	1228	
10	mmHg	 to	SBP	and	DBP,	 respectively,	 for	 individuals	 reported	 to	be	 taking	BP-lowering	1229	
medication	 (94,289	 individuals)59.	 Descriptive	 summary	 statistics	 are	 shown	 in	1230	
Supplementary	Table	1a.	1231	
UKB	analysis	models	1232	
For	the	UKB	GWAS	we	performed	 linear	mixed	model	 (LMM)	association	testing	under	an	1233	
additive	 genetic	model	 of	 the	 three	 (untransformed)	 continuous,	medication-adjusted	 BP	1234	
traits	(SBP,	DBP,	PP)	for	all	measured	and	imputed	genetic	variants	in	dosage	format	using	1235	
the	 BOLT-LMM	 (v2.3)	 software17.	We	 also	 calculated	 the	 estimated	 SNP-wide	 heritability	1236	
(h2)	 in	 our	 data.	 We	 used	 genotyped	 SNPs	 filtered	 for	 MAF	 >	 5%;	 HWE	P	 >	 1	 x	 10-6;	1237	
missingness	<	0.015,	 to	estimate	 the	parameters	of	 the	 linear	mixed	model,	 for	 the	 initial	1238	
modelling	step	only.		Within	the	association	analysis,	we	adjust	for	the	following	covariates:	1239	
sex,	age,	age2,	BMI	and	a	binary	indicator	variable	for	UKB	vs	UK	BiLEVE	to	account	for	the	1240	
different	genotyping	chips.	The	association	analysis	performed	by	BOLT-LMM	(v2.3)	corrects	1241	
for	population	structure	and	cryptic	relatedness	in	very	large	datasets17.	The	genome-wide	1242	
association	analysis	of	all	HRC-imputed	SNPs	was	restricted	to	variants	with	MAF	≥	1%	and	1243	
INFO	>	0.1.	1244	
Genomic	inflation	and	confounding	1245	
We	applied	the	univariate	LD	score	regression	method	(LDSR)18	to	test	for	genomic	inflation	1246	
(expected	 for	 polygenic	 traits	 like	 BP,	 with	 large	 sample	 sizes,	 and	 especially	 also	 from	1247	
analyses	 of	 such	 dense	 genetic	 data	with	many	 SNPs	 in	 high	 LD)60.	 LDSR	 intercepts	 (and	1248	
standard	errors)	were	1.217	 (0.018),	1.219	 (0.020)	and	1.185	 (0.017)	 for	SBP,	DBP	and	PP	1249	
respectively,	and	were	used	to	adjust	the	UKB	GWAS	results	for	genomic	inflation,	prior	to	1250	
the	meta-analysis.	1251	
International	Consortium	for	Blood	Pressure	(ICBP)	GWAS	1252	
ICBP	 GWAS	 is	 an	 international	 consortium	 to	 investigate	 BP	 genetics6.	 We	 combined	1253	
previously	 reported	 post-QC	 GWAS	 data	 from	 54	 studies	 (N=150,134)11,12,61,	 with	 newly	1254	
available	 GWAS	 data	 from	 a	 further	 23	 independent	 studies	 (N=148,890)	 using	 a	 fixed	1255	
effects	inverse	variance	weighted	meta-analysis.	 	The	23	studies	providing	new	data	were:	1256	
ASCOT-SC,	ASCOT-UK,	BRIGHT,	Dijon	3C,	EPIC-CVD,	GAPP,	HCS,	GS:SFHS,	Lifelines,	JUPITER,	1257	
PREVEND,	TWINSUK,	GWAS-Fenland,	 InterAct-GWAS,	OMICS-EPIC,	OMICS-Fenland,	UKHLS,	1258	
GoDARTS-Illumina	and	GoDarts-Affymetrix,	NEO,	MDC,	SardiNIA,	METSIM.		1259	
All	 study	 participants	 were	 of	 European	 ancestry	 and	 were	 imputed	 to	 either	 the	 1000	1260	
Genomes	Project	Phase	1	integrated	release	v.3	[March	2012]	all	ancestry	reference	panel62	1261	
or	 the	 Haplotype	 Reference	 Consortium	 (HRC)	 panel16.	 The	 final	 enlarged	 ICBP	 GWAS	1262	
dataset	included	77	cohorts	(N=299,024	individuals).		1263	
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Definition	of	phenotype	data	and	GWAS	analyses	of	SBP,	DBP	and	PP	were	as	per	previous	1264	
ICBP	 protocol	 for	 54	 studies11,	 extended	 to	 the	 additional	 23	 studies	 for	which	 new	data	1265	
were	 available.	 Full	 study	 names,	 cohort	 information	 and	 general	 study	 methods	 are	1266	
included	in	Supplementary	Table	1b	and	in	Supplementary	Tables	20a-c.	Genomic	control	1267	
was	applied	at	study-level.	The	LDSR	 intercepts	 (standard	error)	 for	the	 ICBP	GWAS	meta-1268	
analysis	 were	 1.089	 (0.012),	 1.086	 (0.012)	 and	 1.066	 (0.011)	 for	 SBP,	 DBP	 and	 PP,	1269	
respectively.	1270	
Meta-analyses	of	discovery	datasets	1271	
We	performed	a	fixed-effects	 inverse	variance	weighted	meta-analysis	using	METAL20,63	to	1272	
obtain	 summary	 results	 from	 the	 combined	 UKB	 and	 ICBP	 GWAS,	 for	 up	 to	 N=757,601	1273	
participants	and	~7.1	M	SNPs	with	MAF	≥	1%	for	variants	present	in	both	the	HRC-imputed	1274	
UKB	data	and	ICBP	meta-analysis	for	all	three	traits.	The	LDSR	intercepts	(standard	error),	in	1275	
the	discovery	meta-analysis	of	UKB	and	 ICBP	were	1.156	 (0.020),	1.160	 (0.021)	and	1.113	1276	
(0.018)	 for	 SBP,	 DBP	 and	 PP	 respectively.	 The	 LDSR	 intercept	 (standard	 error),	 after	 the	1277	
exclusion	of	all	published	BP	variants	(see	below)	in	the	discovery	meta-analysis	of	UKB	and	1278	
ICBP	was	1.090	(0.018),	1.097	(0.017)	and	1.064	(0.015)	 for	SBP,	DBP	and	PP	respectively,	1279	
hence	 showing	 little	 inflation	 in	 the	discovery	GWAS	after	 the	 exclusion	of	 published	 loci	1280	
(Supplementary	Fig.	12).	No	further	correction	was	applied	to	the	discovery	meta-analysis	1281	
of	UKB	and	ICBP	GWAS.	1282	
Previously	reported	variants		1283	
We	 compiled	 from	 the	 peer-reviewed	 literature	 all	 357	 SNPs	 previously	 reported	 to	 be	1284	
associated	with	BP	at	the	time	that	our	analysis	was	completed,	that	have	been	identified	1285	
and	validated	as	the	sentinel	SNP	in	primary	analyses	from	previous	BP	genetic	association	1286	
studies.	 These	 357	 published	 SNPs	 correspond	 to	 274	 distinct	 loci,	 according	 to	 locus	1287	
definition	 of:	 (i)	 SNPs	 within	 ±500kb	 distance	 of	 each	 other;	 (ii)	 SNPs	 in	 Linkage	1288	
Disequilibrium	 (LD),	 using	 a	 threshold	 of	 r2	 ≥	 0.1,	 calculated	 with	 PLINK	 (v2.0).	We	 then	1289	
augment	this	list	to	all	SNPs	present	within	our	data,	which	are	contained	within	these	274	1290	
published	BP	 loci,	 i.e.	 all	 SNPs	which	 are	 located	±500kb	 from	each	of	 the	357	published	1291	
SNPs	and/or	in	LD	with	any	of	the	357	previously	validated	SNPs	(r2	≥	0.1).		1292	
Identification	of	novel	signals:	Two-stage	and	one-stage	study	designs	1293	
To	 identify	novel	 signals	of	association	with	BP,	 two	complementary	 study	designs	 (which	1294	
we	 term	here	 “two-stage	design”	 and	 “one-stage	design”)	were	 implemented	 in	 order	 to	1295	
maximize	the	available	data	and	minimize	reporting	of	false	positive	associations.		1296	
Two-stage	design:	Overview:	1297	
All	of	the	following	criteria	had	to	be	satisfied	for	a	signal	to	be	reported	as	a	novel	signal	of	1298	
association	with	BP	using	our	two-stage	design:		1299	
37		
(i) the	sentinel	SNP	shows	significance	(P	<	1	×	10-6)	in	the	discovery	meta-analysis	1300	
of	UKB	and	ICBP,	with	concordant	direction	of	effect	between	UKB	and	ICBP;	1301	
(ii) the	sentinel	SNP	is	genome-wide	significant	(P	<	5	×	10-8)	in	the	combined	meta-1302	
analysis	 of	 discovery	 and	 replication	 (MVP	 and	 EGCUT)	 (replication,	 described	1303	
below);		1304	
(iii) the	 sentinel	 SNP	 shows	 support	 (P	 <	 0.01)	 in	 the	 replication	 meta-analysis	 of	1305	
MVP	and	EGCUT	alone	(Supplementary	Methods);		1306	
(iv) the	sentinel	SNP	has	concordant	direction	of	effect	between	the	discovery	and	1307	
the	replication	meta-analyses;	1308	
(v) the	sentinel	SNP	must	not	be	located	within	any	of	the	274	previously	reported	1309	
loci	described	above.	1310	
The	 primary	 replicated	 trait	 was	 then	 defined	 as	 the	 BP	 trait	 with	 the	 most	 significant	1311	
association	 from	 the	 combined	 meta-analysis	 of	 discovery	 and	 replication	 (in	 the	 case	1312	
where	a	SNP	was	replicated	for	more	than	one	BP	trait.)	1313	
Two-stage	design:	Selection	of	variants	from	the	discovery	meta-analysis	1314	
We	 considered	 for	 follow-up	 SNPs	 in	 loci	 non-overlapping	 with	 previously	 reported	 loci	1315	
according	to	both	an	LD	threshold	at	r2	of	0.1	and	a	1Mb	interval	region,	as	calculated	by	1316	
PLINK64.	We	obtained	a	 list	 of	 such	 SNPs	with	P	 <	 1	 ×	 10-6	 for	 any	of	 the	 three	BP	 traits,	1317	
which	also	had	concordant	direction	of	effect	between	UKB	vs	ICBP.	By	ranking	the	SNPs	by	1318	
significance	 in	 order	 of	 minimum	 P-value	 across	 all	 BP	 traits,	 we	 performed	 an	 iterative	1319	
algorithm	to	determine	the	number	of	novel	signals	(Supplementary	Methods),	and	identify	1320	
the	sentinel	SNP	(most	significant)	per	locus.	1321	
Two-stage	design:	Replication	analysis	1322	
We	used	two	independent	external	data	sets	for	replication	(Supplementary	Methods).	We	1323	
considered	SNPs	with	MAF	≥	1%	for	an	independent	replication	in	MVP	(max	N	=	220,520)14	1324	
and	 in	 EGCUT	 Biobank	 (N=28,742)15.	 This	 provides	 a	 total	 of	 N	 =	 249,262	 independent	1325	
samples	 of	 European	 descent	 available	 for	 replication.	 Additional	 information	 on	 the	1326	
analyses	 of	 the	 two	 replication	 datasets	 is	 provided	 in	 Supplementary	 Methods	 and	 in	1327	
Supplementary	Table	1c.		1328	
The	two	datasets	were	then	combined	using	fixed	effects	inverse	variance	weighted	meta-1329	
analysis	and	summary	results	 for	all	 traits	were	obtained	 for	 the	replication	meta-analysis	1330	
dataset.		1331	
Two-stage	design:	Combined	meta-analysis	of	discovery	and	replication	meta-analyses	1332	
The	 meta-analyses	 were	 performed	 within	 METAL	 software63	 using	 fixed	 effects	 inverse	1333	
variance	weighted	meta-analysis	 (Supplementary	Methods).	 The	 combined	meta-analysis	1334	
of	both	the	discovery	data	 (N	=	757,601)	and	replication	meta-analysis	 (max	N	=	249,262)	1335	
provided	a	maximum	sample	size	of	N	=	1,006,863.		1336	
One-stage	design:	Overview	1337	
38		
Variants	that	were	looked-up	but	did	not	replicate	according	to	the	two-stage	criteria	were	1338	
considered	in	a	one-stage	design.	All	of	the	following	criteria	had	to	be	satisfied	for	a	signal	1339	
to	be	reported	as	a	novel	signal	of	association	with	BP	using	our	one-stage	criteria:	1340	
i) the	sentinel	SNP	has	P	<	5	×	10-9	in	the	discovery	(UKB+ICBP)	meta-analysis;		1341	
ii) the	sentinel	SNP	shows	support	(P	<	0.01)	in	the	UKB	GWAS	alone;	1342	
iii) 	the	sentinel	SNP	shows	support	(P	<	0.01)	in	the	ICBP	GWAS	alone;	1343	
iv) the	 sentinel	 SNP	 has	 concordant	 direction	 of	 effect	 between	 UKB	 and	 ICBP	1344	
datasets;	1345	
v) The	sentinel	SNP	must	not	be	located	within	any	of	the	274	previously	reported	1346	
loci	described	above	or	the	recently	reported	non-replicated	loci	 from	Hoffman	1347	
et	al.9	(Supplementary	Table	21).	1348	
We	selected	 the	one-stage	P-value	 threshold	 to	be	an	order	of	magnitude	more	stringent	1349	
than	 a	 genome-wide	 significance	P-value,	 so	 as	 to	 ensure	 robust	 results	 and	 to	minimize	1350	
false	 positive	 findings.	 The	 threshold	 of	 P	 <	 5	 ×	 10-9	 has	 been	 proposed	 as	 a	 more	1351	
conservative	 statistical	 significance	 threshold,	 e.g.	 for	 whole-genome	 sequencing-based	1352	
studies21	and	it	was	more	stringent	than	the	suggested	p-value	(1	×	10-8)	we	obtained	from	1353	
our	own	calculations	for	the	number	of	independent	SNPs	tested	in	the	data.	1354	
Selection	of	variants	from	the	meta-analysis	of	UKB	and	ICBP	was	performed	as	described	1355	
above	for	the	two-stage	design.		1356	
Conditional	Analysis	1357	
We	also	performed	 conditional	 analyses	using	 the	GWAS	discovery	meta-analysis	 data,	 in	1358	
order	to	identify	any	independent	secondary	signals	in	addition	to	the	sentinel	SNPs	at	the	1359	
901	loci.	We	used	two	different	methodological	approaches,	each	using	the	Genome-wide	1360	
Complex	Traits	Analysis	(GCTA)	software22:	(i)	full	“genome-wide	conditional	analysis”	with	1361	
joint	multivariate	analysis	 and	 stepwise	model	 selection	across	 all	 three	BP	 traits;	 and	 (ii)	1362	
“locus-specific	 conditional	 analysis”	 for	 the	 primary	 BP	 trait	 conditioning	 on	 the	 sentinel	1363	
SNPs	within	 each	 locus	 (Supplementary	Methods).	 For	 robustness,	 secondary	 signals	 are	1364	
only	 reported	 if	 obtained	 from	 both	 approaches.	 All	 secondary	 signals	 were	 selected	 at	1365	
genome-wide	 significance	 level,	 with	 MAF	 ≥	 1%	 and	 confirmed	 to	 be	 pairwise-LD-1366	
independent	(r2	<	0.1),	as	well	as	not	being	in	LD	with	any	of	the	published	or	sentinel	SNPs	1367	
at	 any	of	 the	901	BP-associated	 loci	 (r2	 <	 0.1).	 In	 all	 cases	 the	UKB	data	was	used	 as	 the	1368	
reference	 genetic	 data	 for	 LD	 calculation,	 restricted	 to	 individuals	 of	 European	 ancestry	1369	
only.	1370	
Functional	analyses:	Variants	1371	
We	used	an	integrative	bioinformatics	approach	to	collate	functional	annotation	at	both	the	1372	
variant	level	(for	each	sentinel	SNP	within	all	BP	loci)	and	the	gene	level	(using	SNPs	in	LD	r2	1373	
≥	0.8	with	the	sentinel	SNPs).	At	the	variant	level,	we	use	Variant	Effect	Predictor	(VEP)	to	1374	
obtain	comprehensive	characterization	of	variants,	including	consequence	(e.g.	downstream	1375	
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or	 non-coding	 transcript	 exon),	 information	 on	 nearest	 genomic	 features	 and,	 where	1376	
applicable,	 amino	 acid	 substitution	 functional	 impact,	 based	 on	 SIFT	 and	 PolyPhen.	 The	1377	
biomaRt	R	package	is	used	to	further	annotate	the	nearest	genes.	1378	
We	evaluate	all	SNPs	in	LD	(r2	≥	0.8)	with	our	novel	sentinel	SNPs	for	evidence	of	mediation	1379	
of	 expression	 quantitative	 trait	 loci	 (eQTL)	 in	 all	 44	 tissues	 using	 the	 Genotype-Tissue	1380	
Expression	(GTEx)	database,	to	highlight	specific	tissue	types	which	show	eQTLs	for	a	larger	1381	
than	 expected	 proportion	 of	 novel	 loci.	 We	 further	 seek	 to	 identify	 novel	 loci	 with	 the	1382	
strongest	evidence	of	eQTL	associations	in	arterial	tissue,	in	particular.	A	locus	is	annotated	1383	
with	a	given	eGene	only	if	the	most	significant	eQTL	SNP	for	the	given	eGene	is	in	high	LD	(r2	1384	
≥	0.8)	with	the	sentinel	SNP,	suggesting	that	the	eQTL	signal	co-localises	with	the	sentinel	1385	
SNP.	1386	
We	annotated	nearest	genes,	eGenes	(genes	whose	expression	is	affected	by	eQTLs)	and	Hi-1387	
C	 interactors	with	HUVEC,	HVMSC	and	HAEC	expression	from	the	Fantom5	project.	Genes	1388	
that	 had	 higher	 then	median	 expression	 levels	 in	 the	 given	 cell	 types	 were	 indicated	 as	1389	
expressed.	1390	
To	identify	SNPs	in	the	novel	loci	that	have	a	non-coding	functional	effect	(influence	binding	1391	
of	 transcription	 factors	 or	 RNA	 polymerase,	 or	 influence	 DNase	 hypersensitivity	 sites	 or	1392	
histone	modifications),	we	used	DeepSEA,	a	deep	learning	algorithm,	that	learnt	the	binding	1393	
and	 modification	 patterns	 of	 ~900	 cell/factor	 combinations65.	 A	 change	 of	 >0.1	 in	 the	1394	
binding	 score	 predicted	 by	DeepSEA	 for	 the	 reference	 and	 alternative	 alleles	 respectively	1395	
has	been	shown	to	have	high	true	positive	rate	~80-95%	and	low	false	positive	rate	~5-10%,	1396	
therefore	we	used	this	cut-off	to	find	alleles	with	non-coding	functional	effect.	1397	
We	 identify	 potential	 target	 genes	 of	 regulatory	 SNPs	 using	 long-range	 chromatin	1398	
interaction	 (Hi-C)	 data	 from	 HUVECs23,	 aorta,	 adrenal	 glands,	 neural	 progenitor	 and	1399	
mesenchymal	 stem	 cell,	which	 are	 tissues	 and	 cell	 types	 that	 are	 considered	 relevant	 for	1400	
regulating	BP24.	Hi-C	data	are	corrected	for	genomic	biases	and	distance	using	the	Hi-C	Pro	1401	
and	 Fit-Hi-C	 pipelines	 according	 to	 Schmitt	 et	 al.	 (40kb	 resolution	 –	 correction	 applied	 to	1402	
interactions	with	50kb-5Mb	span)24.	We	find	the	most	significant	promoter	interactions	for	1403	
all	potential	regulatory	SNPs	(RegulomeDB	score	£	5)	in	LD	(r2	≥	0.8)	with	our	novel	sentinel	1404	
SNPs	and	published	SNPs,	and	choose	 the	 interactors	with	 the	SNPs	of	highest	 regulatory	1405	
potential	to	annotate	the	loci.	1406	
We	then	perform	overall	enrichment	testing	across	all	 loci.	Firstly,	we	use	DEPICT66	 (Data-1407	
driven	 Expression	 Prioritized	 Integration	 for	 Complex	 Traits)	 to	 identify	 tissues	 and	 cells	1408	
which	 are	 highly	 expressed	 at	 genes	 within	 the	 BP	 loci.	 DEPICT	 uses	 a	 large	 number	 of	1409	
microarrays	 (~78K)	 to	 identify	cells	and	 tissues	where	 the	genes	are	highly	expressed	and	1410	
uses	pre-computed	GWAS	phenotypes	to	adjust	 for	cofounding	sources.	Secondly,	we	use	1411	
DEPICT	to	test	for	enrichment	in	gene	sets	associated	with	biological	annotations	(manually	1412	
curated	 and	molecular	 pathways,	 phenotype	data	 from	mouse	KO	 studies).	Using	 the	 co-1413	
expression	data	DEPICT	calculates	a	probability	for	each	gene	to	belong	to	a	given	gene	set	1414	
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and	 uses	 this	 to	 weight	 the	 enrichment	 of	 the	 genes	 present	 in	 the	 tested	 loci.	 DEPICT	1415	
provides	 a	 P-value	 of	 enrichment	 and	 false	 discovery	 rates	 adjusted	 P-values	 for	 each	1416	
tissue/cells	or	gene	set	tested.	We	report	significant	enrichments	with	a	false	discovery	rate	1417	
<0.01.	 The	 variants	 tested	 were	 i)	 the	 357	 published	 BP	 associated	 SNPs	 at	 the	 time	 of	1418	
analysis	and	ii)	a	set	including	all	(published	and	novel)	variants	(with	novel	SNPs	filtered	by	1419	
highest	significance,	P	<	1	×	10-12).	1420	
Furthermore,	 to	 investigate	 cell	 type	 specific	 enrichment	 within	 DNase	 I	 sites,	 we	 used	1421	
FORGE,	which	tests	for	enrichment	of	SNPs	within	DNase	I	sites	 in	123	cell	types	from	the	1422	
Epigenomics	 Roadmap	 Project	 and	 ENCODE25	 (Supplementary	 Methods).	 Two	 analyses	1423	
were	compared	(i)	using	published	SNPs	only;	(ii)	using	sentinel	SNPs	at	all	901	loci,	in	order	1424	
to	evaluate	the	overall	tissue	specific	enrichment	of	BP	associated	variants.	1425	
Functional	analyses:	Genes	1426	
At	 the	 gene	 level,	 we	 use	 Ingenuity	 Pathway	 Analysis	 (IPA)	 software	 (IPA®,	 QIAGEN	1427	
Redwood	 City)	 to	 review	 genes	 with	 prior	 links	 to	 BP,	 based	 on	 annotation	 with	 the	1428	
“Disorder	of	Blood	Pressure”,	 “Endothelial	Development”	and	 “Vascular	Disease”	Medline	1429	
Subject	 Heading	 (MESH)	 terms.	 We	 used	 the	 Mouse	 Genome	 Informatics	 (MGI)	 tool	 to	1430	
identify	BP	and	cardiovascular	relevant	mouse	knockout	phenotypes	for	all	genes	linked	to	1431	
BP	in	our	study.	We	also	used	IPA	to	identify	genes	that	interact	with	known	targets	of	anti-1432	
hypertensive	drugs.	Genes	were	also	evaluated	for	evidence	of	small	molecule	druggability	1433	
or	known	drugs	based	on	queries	of	the	Drug	Gene	Interaction	database.	1434	
Lookups	in	non-European	ancestries	1435	
As	 a	 secondary	 analysis,	 we	 look	 up	 all	 known	 and	 novel	 BP-associated	 SNPs	 in	 African	1436	
(7,782)	 and	 South	 Asian	 (10,322)	 ancestry	 samples	 of	 UKB.	 An	 equivalent	 GWAS-LMM	1437	
analysis	 was	 performed	 using	 BOLT-LMM	 for	 each	 BP	 trait	 within	 each	 ancestry	1438	
(Supplementary	Methods).	1439	
Effects	on	other	traits	and	diseases	1440	
We	 query	 SNPs	 against	 GWAS	 catalog26	 and	 PhenoScanner27,	 including	 genetics	 and	1441	
metabolomics	databases,	to	investigate	cross-trait	effects,	extracting	all	association	results	1442	
with	genome-wide	significance	at	P	<	5	×	10-8	for	all	SNPs	in	high	LD	(r2	≥	0.8)	with	the	535	1443	
sentinel	novel	SNPs,	to	highlight	the	loci	with	strongest	evidence	of	association	with	other	1444	
traits.	We	further	evaluated	these	effects	using	DisGeNET,	a	resource	that	 integrates	data	1445	
from	expert	 curated	 repositories,	GWAS	catalogues,	animal	models	and	 the	 literature28,29.	1446	
Specifically,	at	 the	SNP	 level,	overlaps	with	DisGeNET	terms	were	computed,	with	roughly	1447	
the	same	number	of	markers	 in	the	published	and	novel	BP	loci.	Thus,	given	the	expected	1448	
saturation	of	 the	overlaps,	a	more	than	double	 increase	 indicates	 that	strong	associations	1449	
are	more	frequent	for	the	novel	BP	loci.	At	the	gene	level,	overrepresentation	enrichment	1450	
analysis	 (ORA)	 with	 WebGestalt67	 on	 the	 nearest	 genes	 to	 all	 BP	 loci	 was	 carried	 out.	1451	
Moreover,	we	 tested	sentinel	SNPs	at	all	published	and	novel	 (N=901)	 loci	 for	association	1452	
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with	lifestyle	related	data	including	food,	water	and	alcohol	intake,	anthropomorphic	traits	1453	
and	 urinary	 sodium,	 potassium	 and	 creatinine	 excretion	 using	 the	 recently	 developed	1454	
Stanford	Global	Biobank	Engine	and	the	Gene	ATLAS68.	Both	are	search	engines	for	GWAS	1455	
findings	 for	 multiple	 phenotypes	 in	 UK	 Biobank.	 We	 used	 a	 Bonferroni	 corrected	1456	
significance	threshold	of	P	<	1	×	10-6	to	deem	significance.	1457	
Genetic	risk	scores	and	percentage	of	variance	explained		1458	
We	calculated	a	genetic	risk	score	(GRS)	to	provide	an	estimate	of	the	combined	effect	of	1459	
the	BP	raising	variants	on	BP	and	risk	of	hypertension,	and	applied	this	to	the	UKB	data.	We	1460	
first	create	two	trait-specific	weighted	GRSs	(i.e.	SBP,	DBP),	for	all	pairwise-independent,	LD-1461	
filtered	(r2	<	0.1)	previously	reported	variants	and	535	novel	sentinel	variants	combined.	For	1462	
the	previously	 reported	variants,	we	weight	BP	 increasing	alleles	by	 the	 trait-specific	beta	1463	
coefficients	from	the	new	ICBP	meta-analysis	GWAS	that	 is	part	of	the	discovery	stage	(to	1464	
minimize	winner’s	 curse	 bias	 compared	 to	 using	 UKB	where	 the	majority	 of	 discovery	 of	1465	
published	SNPs	has	been	derived).	For	the	novel	variants,	beta	coefficients	of	the	replication	1466	
meta-analysis	for	each	BP	trait	are	used	as	independent,	unbiased	weights.	We	then	derive	1467	
a	single	BP	GRS	as	the	average	of	the	GRS	for	SBP	and	DBP,	and	standardize	it	to	have	mean	1468	
zero	 and	 standard	 deviation	 of	 one.	 GRS	 were	 calculated	 for	 487,409	 individuals.	 For	1469	
statistical	 analysis	 of	 GRS,	 we	 focused	 on	 unrelated	 individuals	 only.	 The	 UKB	 database	1470	
included	 502,638	 individuals.	 We	 removed	 pregnant	 women	 (n=372)	 and	 withdrawn	1471	
individuals	 (n=19).	We	merged	 GRS	 and	 phenotype	 data	 (n	 merged=487,048)	 and	 excluded	1472	
individuals	with	 first	 or	 second	 degree	 related	 individuals.	 The	 final	 database	 for	 analysis	1473	
included	423,713	unrelated	 individuals	of	European	ancestry	of	whom	392,092	 individuals	1474	
were	free	of	cardiovascular	events	at	baseline.		1475	
We	assess	the	association	of	the	continuous	GRS	variable	on	BP	by	simple	linear	regression,	1476	
and	use	logistic	regression	to	examine	the	association	of	the	GRS	with	risk	of	hypertension,	1477	
with	and	without	adjustment	for	sex.	We	then	use	linear	and	logistic	regression	to	compare	1478	
BP	levels	and	risk	of	hypertension,	respectively,	for	individuals	in	the	top	vs	bottom	quintiles	1479	
of	 the	GRS	distribution.	Similar	analyses	were	performed	 for	 the	 top	vs	bottom	deciles	of	1480	
the	GRS	 distribution.	 All	 analyses	were	 restricted	 to	 the	 392,092	 unrelated	 individuals	 of	1481	
European	ancestry	from	UKB.		As	a	sensitivity	analysis	to	assess	for	evidence	of	bias	in	the	1482	
UKB	 results,	 we	 also	 carried	 out	 similar	 analyses	 in	 Airwave,	 an	 independent	 cohort	 of	1483	
N=14,004	unrelated	participants	of	European	descent30	(Supplementary	Methods).	1484	
We	 also	 assessed	 the	 association	 of	 the	 GRS	 with	 cardiovascular	 disease	 in	 unrelated	1485	
participants	 in	 UKB	 data,	 based	 on	 self-reported	 medical	 history,	 and	 linkage	 to	1486	
hospitalization	and	mortality	data.	We	use	logistic	regression	with	binary	outcome	variables	1487	
for	 composite	 incident	 cardiovascular	 disease	 (Supplementary	 Methods),	 incident	1488	
myocardial	infarction	and	incident	stroke	(using	the	algorithmic	UKB	definitions)	and	GRS	as	1489	
explanatory	variable	(with	and	without	sex	adjustment).			1490	
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We	also	 calculated	 the	 association	of	 this	GRS	with	BP	 in	unrelated	 individuals	 of	African	1491	
(N=6,970)	and	South	Asian	(N=8,827)	ancestry	from	the	UKB	using	the	approach	described	1492	
above,	 to	 see	 whether	 BP-associated	 SNPs	 identified	 from	 GWAS	 predominantly	 in	1493	
Europeans	are	also	associated	with	BP	in	populations	of	non-European	ancestry.	1494	
We	 calculated	 the	 percentage	 of	 variance	 in	 BP	 explained	 by	 genetic	 variants	 using	 the	1495	
independent	Airwave	cohort	 (N=14,004).	We	generated	the	residuals	 from	a	regression	of	1496	
each	 trait	 against	 age,	 age2,	 sex	and	BMI.	We	 then	 fit	 a	 second	 linear	model	 for	 the	 trait	1497	
residuals	with	the	GRS	plus	the	top	10	principal	components,	and	estimated	the	percentage	1498	
variance	 of	 the	 dependent	 (BP)	 variable	 explained	 by	 the	 GRS.	 We	 considered	 three	1499	
different	levels	of	the	GRS:	(i)	all	pairwise-independent,	LD-filtered	(r2	<	0.1)	published	SNPs	1500	
within	 the	 known	 loci;	 (ii)	 all	 known	 SNPs	 and	 sentinel	 SNPs	 at	 novel	 loci;	 (iii)	 all	1501	
independent	signals	at	all	901	known	and	novel	loci	including	the	163	secondary	SNPs.	1502	
Data	availability	statement		1503	
The	 genetic	 and	 phenotypic	 UKB	 data	 are	 available	 upon	 application	 to	 the	 UK	 Biobank	1504	
(https://www.ukbiobank.ac.uk).	 All	 replication	 data	 generated	 during	 this	 study	 are	1505	
included	in	the	published	article.	For	example,	association	results	of	 look-up	variants	from	1506	
our	replication	analyses	and	the	subsequent	combined	meta-analyses	are	contained	within	1507	
the	Supplementary	Tables	provided.	1508	
Ethics	Statement	1509	
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